Latest News

Experienced QP Robert Smith joins the CBF as external consultant

Posted 28/05/2015

Due to the increasing demand of process development and manufacture of novel product types we are pleased to announce that we secured the services of QP Robert Smith of Smiro Qualitas Ltd. Robert has over 25 years experience in the pharmaceutical industry, including his role as Global Head of Quality for the Clinical Pharmacy Research Services at ...

New malaria vaccine shows promise in field trial

Posted 08/05/2015

The volunteers in this phase II clinical trial received prime-boost vaccination with the chimpanzee adenovirus 63 (ChAd63) and a modified vaccinia Ankara (MVA) vaccine, both encoding the malaria antigen ME-TRAP. It was conducted at the Kenya Medical Research Institute (KEMRI) field site located in Junju, Kilifi County, Kenya. Healthy adult male volunteers were randomly allocated to vaccination with either the T cell–inducing malaria vaccine candidates or a rabies control vaccine. The authors found that the volunteers receiving the T cell-inducing vaccine had a 67% reduction in the risk of malaria infection during 8 weeks of follow-up.

See also report on BBC News.

CBF, Jenner Institute Researchers and MHRA Innovation Office Work Together to Develop New Malaria Vaccine

CBF, Jenner Institute Researchers and MHRA Innovation Office Work Together to Develop New Malaria Vaccine

Posted 03/03/2015

Through engagement with the University of Oxford the MHRA Innovation Office has helped contribute to the development of a viral vector, which is used as a carrier of genetic material to help treat a specific disease. The MHRA helped facilitate the strategic project planning by introducing Jenner Institute researchers to the relevant agency teams at the correct times. These included colleagues in the clinical trials teams, the good manufacturing practice (GMP) inspectorate, the pharmaceutical assessors and the toxicologists.

Eleanor Berrie, QP, Clinical BioManufacturing Facility, the University of Oxford said:

“We needed to work quickly to find the answers to questions that would help us develop an effective programme of research. The experts at MHRA were quick to recognise our innovative approach and worked with us closely at a number of vital milestones, which in turn helped us bring this breakthrough to the fore.

See the full MHRA case study.

First results of ebola vaccine trial shows acceptable safety profile

Posted 29/01/2015

The GSK/NIH chimpanzee adenovirus vaccine QP certified and labelled by the CBF is well tolerated and generates immune responses in the trial with 60 volunteers conducted by the University of Oxford.

CBF has labelled and certified booster vaccine for Ebola trial at University of Oxford

CBF has labelled and certified booster vaccine for Ebola trial at University of Oxford

Posted 04/12/2014

The CBF has recently labelled and certified the modified vaccinia Ankara (MVA) virus booster vaccine by Bavarian Nordic A/S. 30 volunteers who already received the adenovirus vaccine (GSK) will also receive the MVA vaccine to boost immune responses.

Hepatitis C vaccine manufactured at CBF successfully tested in clinical trial

Hepatitis C vaccine manufactured at CBF successfully tested in clinical trial

Posted 06/11/2014

The Phase I trial was led by Prof Ellie Barnes and used a vaccine first manufactured by the CBF in 2008. The vaccine is based on the chimpanzee adeno ChAd3 vector backbone to which genes encoding four proteins from hepatitis C virus were added (developed by Okairos in Italy, now owned by GSK). In the study, a prime-boost vaccination strategy using ...

Ebola vaccine trial started in Mali

Ebola vaccine trial started in Mali

Posted 24/10/2014

The cAd3 ebola vaccine, developed by Glaxo Smith Kline and the US National Institute of Health and imported by the CBF, was recently labelled and shipped for a Phase Ib vaccine trial taking place in Mali. The trial is run by the University of Maryland in conjunction with the Malian Ministry of Health and 40 volunteers will be vaccinated to further ...

Ebola Vaccine Trial - update

Ebola Vaccine Trial - update

Posted 17/09/2014

The CBF has finished the importation, labelling and certification of the cAd3 ebola vaccine. The trial was fast tracked by the MHRA and ethics committee in record time, allowing the Phase I trial lead by Prof Adrian Hill from the Jenner Institute to begin today. We delivered the adenovirus vaccine to the clinical trial site this morning and the ...

Ebola Vaccine Trial - update

Ebola Vaccine Trial - update

Posted 09/09/2014

The Ebola vaccine trial run by the Jenner Institute (University of Oxford) has now been given regulatory approval and is open for recruitment of healthy volunteers. The CBF will import, certify and label the adenovirus vaccine for the Phase I trial including 60 volunteers within the next few days. The vaccine, which was co-developed by Glaxo ...

CBF to import, label and QP certify Ebola vaccine used in Phase I trial in Oxford

CBF to import, label and QP certify Ebola vaccine used in Phase I trial in Oxford

Posted 01/09/2014

In the last few days there were many news stories about the upcoming Phase I Ebola vaccine trials in the national and international press, e.g.:  The Independent, Daily Mail, German Press, Austrian Press. The trial including 60 heatlhy volunteers is led by Prof Adrian Hill from the Jenner Institute, and the CBF will play an important role in ...